Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDROSERPINE PLUS (R-H-H) vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Hydroflumethiazide: 2-3 h; reserpine: 50-100 h (biphasic); hydralazine: 2-4 h (fast acetylators), 6-8 h (slow acetylators).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hydrochlorothiazide: Not metabolized, excreted unchanged in urine. Reserpine: Metabolized in the liver via hydrolysis and conjugation. Hydralazine: Acetylation in the liver via N-acetyltransferase (NAT2).
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Hydroflumethiazide: renal (50-65% unchanged); reserpine: renal (30%) and fecal (60%) as metabolites; hydralazine: renal (85% as metabolites, 10% unchanged).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Hydroflumethiazide: 70% (albumin); reserpine: 96%; hydralazine: 87% (albumin and alpha-1 acid glycoprotein).
~90%, primarily to albumin
Hydroflumethiazide: 3.6 L/kg; reserpine: 10-20 L/kg; hydralazine: 1.6 L/kg (central) and 2.7 L/kg (total).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: hydroflumethiazide 70-75%; reserpine 50-60%; hydralazine 30-50% (first-pass metabolism).
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 1 tablet orally once daily; monitor electrolytes. No adjustment needed for Cr Cl >50 m L/min.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B: use with caution; reduce dose to 1 tablet orally once daily and monitor for encephalopathy.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for pediatric use due to lack of safety and efficacy data.
Not recommended for pediatric use; safety in children under 12 years not established.
Start with 1 tablet orally once daily; titrate slowly. Monitor for orthostatic hypotension, electrolyte imbalances, and CNS effects. Avoid use in patients with depression.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Reserpine: May cause mental depression, especially in patients with a history of depression. Discontinue at first signs of depression.
None
Hydrochlorothiazide: Electrolyte imbalance, hyperglycemia, hyperuricemia, lupus exacerbation. Reserpine: Mental depression, peptic ulcer, bradycardia. Hydralazine: Drug-induced lupus, tachycardia, myocardial ischemia, peripheral neuritis.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Reserpine: Hypersensitivity, history of depression, active peptic ulcer, ulcerative colitis, pheochromocytoma. Hydralazine: Hypersensitivity, mitral valve rheumatic heart disease, coronary artery disease. Hydrochlorothiazide: Anuria, hypersensitivity to sulfonamides, severe renal failure.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, spinach) due to the potassium-sparing effect of the combination? Note: Actually HYDROSERPINE PLUS contains hydrochlorothiazide which is potassium-wasting; reserpine and hydralazine do not affect potassium significantly. Thus, potassium supplementation may be needed; monitor potassium levels. Limit sodium intake to control blood pressure. Avoid tyramine-rich foods (e.g., aged cheeses, cured meats) due to reserpine's potential to cause hypertensive crisis? Reserpine is not a MAOI, but caution with high-tyramine foods is advised.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not teratogenic in animal studies. Second and third trimesters: Hydrochlorothiazide may cause fetal electrolyte disturbances and thrombocytopenia; reserpine may cause neonatal bradycardia and hypotension; hydralazine may cause fetal hypotension and reflex tachycardia.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Hydrochlorothiazide is excreted in breast milk in low concentrations (M/P ratio 0.6); reserpine is excreted (M/P ratio unknown, but may cause galactorrhea and infant sedation); hydralazine is excreted in low amounts (M/P ratio not well defined). Theoretical risk of hypotensive effects in infants. Caution recommended.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments have been established for the combination; however, increased plasma volume and renal clearance in pregnancy may reduce efficacy, potentially requiring dose increase or alternative therapy. Individualize based on blood pressure response and avoid volume depletion.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Hydralazine and hydrochlorothiazide can cause lupus-like syndrome; monitor for arthralgias, rash, and fever. Reserpine depletes catecholamines, leading to potential sedation and depression; use with caution in patients with history of mood disorders. Check serum potassium and uric acid levels due to thiazide component.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed; do not skip doses or double up.,Rise slowly from sitting or lying down to prevent dizziness.,Avoid driving or operating machinery until you know how this drug affects you.,Report any unusual weight gain, swelling, or shortness of breath.,Contact your doctor if you experience joint pain, fever, or rash.,Do not stop taking this medicine abruptly; it may cause blood pressure to rise.,Limit alcohol consumption as it can increase dizziness and drowsiness.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDROSERPINE PLUS (R-H-H) vs ALDORIL 15, answered by our medical review team.
HYDROSERPINE PLUS (R-H-H) is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines from peripheral sympathetic nerve endings, reducing sympathetic tone. Hydralazine directly relaxes arteriolar smooth muscle, decreasing systemic vascular resistance.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDROSERPINE PLUS (R-H-H) and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDROSERPINE PLUS (R-H-H) is: 1 tablet orally twice daily. Each tablet contains hydrochlorothiazide 25 mg, reserpine 0.125 mg, and hydralazine hydrochloride 25 mg.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDROSERPINE PLUS (R-H-H) and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDROSERPINE PLUS (R-H-H) is classified as Category C. First trimester: Hydrochlorothiazide is associated with an increased risk of neural tube defects and oral clefts; reserpine may cause respiratory distress; hydralazine is not terat. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.